Carcinoma Cervix

Treatment policies

External Beam Radiation Therapy

SK Shrivastava,
U Mahantshetty, R Engineer, S Chopra, SV Jamema, DD Deshpande

Tata Memorial Hospital, Parel, Mumbai 400012
Introduction

- **Global scenario**
  - 2nd commonest malignancy in women
  - 4,50,000 new cases annually
  - 2,10,000 deaths
    (Ferlay et al. Cancer incidence and mortality worldwide, 1998)

- **India**
  - 20-50% of all cancers in women
  - 1,00,000 new cases yearly

- **TMH**
  - 22% of all cancers recorded (1997 registry)
Pre-treatment Evaluation

I   Establish tissue diagnosis

II  Staging of disease

III Systemic evaluation
Pre-treatment Evaluation

I. **Diagnostic:**
   - Biopsy
   - Colposcopic guided biopsy
   - Endo cervical curettage
   - Cone biopsy

II. **Staging:**
   - Pelvic Examination / EUA
   - Chest x-ray
   - Cystoscopy, Proctoscopy  if indicated
   - IVP, Ba-enema  if indicated
Pre-treatment Evaluation

- Haematological & biochemical parameters

- Optional studies:
  - USG,
  - CT Scan / MRI
  - PET

Joint Clinic
Principles of Treatment

Plan treatment to include (clinical):

- Disease at the primary site
- Local extension to parametria & vagina
- Regional spread to pelvic nodes
- Spread to para-aortic nodes
- Possible systemic spread
Factors for Treatment

- Age of the patient
- Stage of disease
- Tumour histology
- Wish to preserve ovarian function & fertility
- Choice of treatment options
Disease Spectrum

- Premalignant
- Preinvasive
- Microinvasive
- Invasive
Carcinoma In Situ

Treatment

- Conization of cervix
- Total abdominal hysterectomy
- Vaginal hysterectomy
- LAVH (Laparoscopically Assisted Vaginal Hysterectomy)

Pelvic lymphadenectomy: No role
Carcinoma-in-situ
Is Hysterectomy Justified?

• 18 out of 5442 women (0.3%) with CIS treated by conization later developed invasive cancer.

  Vs

• 38 out of 8995 women (0.4%) with CIS treated by hysterectomy later developed invasive cancer of vagina

Hysterectomy not justified based on current evidence.
Stage I  Carcinoma strictly confined to cervix

Stage Ia  Microscopic lesion

  Ia1  Minimal microscopically evident stromal invasion up to 3mm and horizontal spread up to 7mm

  Ia2  Stromal invasion 3.1 to 5mm and horizontal spread up to 7mm
Stage Ia  Natural History

- **Lymph node metastases related to:**
  - Depth of stromal invasion
  - Lympho-vascular space invasion

- **Incidence of lymph node metastasis:**
  - Stage Ia1: 0.5% (Averette 1976)
  - Stage Ia2: 3.5% (Averette 1976), 3.9% (Simon 1986), 5 - 8% (Literature)

**Rationale:** To identify a subgroup with a negligible risk of LN mets & who may be treated with less than radical therapy (SGO 1993)
FIGO STAGING

EARLY

I-IIIA

SURGERY

RADICAL RADIOTHERAPY

+ CHEMOTHERAPY

ADVANCED

IIB – IVA

IVA-IVB / REC

PALLIATION

• RADIOTHERAPY

• CHEMOTHERAPY

November 03, 2014

Dhaka
Stage-Ia Treatment

Non-visible Lesion
Cone Biopsy

Stage-Ia1 disease
- Margins -ve
- LVSI absent
  - Class I TAH/VH
  - Radical cone if fertility desired

Stage-Ia2 disease
- Margins +ve
- LVSI present
  - Class II Radical Hyst.
    - with BPLND,
      - or
    - Brachytherapy
Stage Ib

Lesions of greater dimensions than Stage Ia whether seen clinically or not

Stage Ib1- Lesion $\leq 4$ cm

Stage Ib2- Lesion $> 4$ cm
STAGE Ib & IIa TREATMENT

Class III radical hysterectomy
With BPLND
Or
Radical radiation therapy
(Ext + Brachy)

Choice of treatment determined by age, menopausal status, ovarian preservation, co-morbid conditions, patient’s wish & availability of expertise in surgery & RT (NIH Guidelines 1997)
Stage Ib and IIA
Radical surgery vs Radical RT

**Non randomised data:**

Both Rx modalities are comparable vis-à-vis locoregional control & 5 yr survival
(Roddick 1971, Newton 1975, Hoskins 1987)

**Randomised data:**
(Morley and Seski 1976; Landoni et al 1997)
Stage Ib & IIa Treatment
Surgery Vs. Radiation Therapy (N=343)

- Prospective RCT: 169 received Radical surgery & 158 received Radical RT
- 108 in the surgery arm also received adjuvant RT (64%) while 61 (20%) received only Surgery
- 25-26% recurrence in both the arms
- 5 year survival: DFS 83% surgery, 74% RT (p=NS)
- Morbidity: 28% in surgery arm and 12% in RT arm (mainly chronic bladder dysfunction and hydroureteronephrosis: May be related to RT)

Landoni 1997
Stage Ib & IIa: Treatment

Surgery Vs. Radiation Therapy

- Both radical surgery & radical RT equally good options of management: No survival benefit with either modality.
- Combination of surgery & RT has the worst morbidity.
- Optimum therapy for each patient should take into account factors such as menopausal status, age, patient’s wish, medical illness, histology type & cervical diameter.

- Adjuvant RT: Does it impact survival or only adds morbidity?

Landoni 1997
# Radical Hysterectomy: Survival

<table>
<thead>
<tr>
<th>Author</th>
<th>Year</th>
<th>No</th>
<th>5 y Surv%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Park</td>
<td>1973</td>
<td>126</td>
<td>91.0</td>
</tr>
<tr>
<td>Morley</td>
<td>1976</td>
<td>156</td>
<td>87.2</td>
</tr>
<tr>
<td>Hoskins</td>
<td>1976</td>
<td>47</td>
<td>89.4</td>
</tr>
<tr>
<td>Sall</td>
<td>1979</td>
<td>219</td>
<td>90.0</td>
</tr>
<tr>
<td>Lerner</td>
<td>1980</td>
<td>48</td>
<td>91.7</td>
</tr>
<tr>
<td>Powell</td>
<td>1984</td>
<td>103</td>
<td>90.3</td>
</tr>
<tr>
<td>Kenter</td>
<td>1989</td>
<td>213</td>
<td>87.3</td>
</tr>
<tr>
<td>Lee</td>
<td>1989</td>
<td>343</td>
<td>87.2</td>
</tr>
<tr>
<td>Ayhan</td>
<td>1991</td>
<td>270</td>
<td>80.1</td>
</tr>
<tr>
<td>Hopkins</td>
<td>1991</td>
<td>213</td>
<td>92.5</td>
</tr>
<tr>
<td>AFTER 1970</td>
<td>1738</td>
<td></td>
<td>87.9</td>
</tr>
</tbody>
</table>
Advantages Of Radical Surgery

- Accurate surgicopathologic staging
- High risk group for adjuvant therapy identified
- Preserves ovarian function
- Maintains better vaginal function
- Most complications are early and can be corrected
- Treatment period is short
- Pelvic rec can be successfully cured by RT
Role Of Lymphadenectomy

• Accurate surgicopathological staging
• Prognostication
• High risk group identified
• Therapeutic in presence of micro mets
• Decreases mortality from persistent disease
• Aids central disease clearance
• Extent: Obturator LND adequate if -ve Else: PLND

No evidence of survival benefit in RCTs
Trachelectomy

- Fertility preserving radical surgery pioneered by Dargent (1994)
- Eligibility: Stage Ib1 < 2 cms lesion in young women desirous of fertility preservation
- Combined with open / lap PLND
- Relapse rate 3.4% (4/130 in 4 series)

No RCT comparing trachelectomy with Rad Hysterectomy
Prognostic Factors for Relapse After Radical Hysterectomy

Positive nodes   }  High
Positive cut margins  }  risk
Positive parametria  }

Deep stromal invasion  }
Large tumour diameter  }  Intermediate
LVSI  }  risk
### Stage Ib/IIa

**Impact of Lymph Node Metastases**

<table>
<thead>
<tr>
<th></th>
<th>Survival (%)</th>
<th>Relapse (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>LN -ve</td>
<td>95.8</td>
<td>-</td>
</tr>
<tr>
<td>LN +ve</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pelvic</td>
<td>63.5</td>
<td>32</td>
</tr>
<tr>
<td>PA</td>
<td>40.8</td>
<td>57</td>
</tr>
<tr>
<td>Pelvic+PA</td>
<td>18.4</td>
<td>73.7</td>
</tr>
</tbody>
</table>
Early Stage Carcinoma Cervix- Primary Surgery  
Intermediate Risk: Role of Adjuvant therapy

**GOG 92 : RCT (Gynae Oncol 73 ;177-83: 1999)**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>No Adj RT N = 140</th>
<th>Adj RT N = 137</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>2 yr RFS</td>
<td>79%</td>
<td>88%</td>
<td>.008</td>
</tr>
<tr>
<td>2 yr OAS</td>
<td>79%</td>
<td>87%</td>
<td>.008</td>
</tr>
<tr>
<td>Pelvic rec</td>
<td>21%</td>
<td>13%</td>
<td></td>
</tr>
<tr>
<td>Dist mets</td>
<td>7%</td>
<td>2%</td>
<td></td>
</tr>
</tbody>
</table>

**ADJUVANT PELVIC RT IS BENEFICIAL**

“Grade A”
Early Stage Carcinoma Cervix- Primary Surgery  
High Risk : Role of Adjuvant therapy

**Intergroup 0107 : RCT (Gynae Oncol 73 ;177-83: 1999)**

<table>
<thead>
<tr>
<th>Outcome</th>
<th>PO RT N = 116</th>
<th>PORT+CTRT N = 127</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 yr RFS</td>
<td>63%</td>
<td>80%</td>
<td>.001</td>
</tr>
<tr>
<td>4 yr OAS</td>
<td>71%</td>
<td>81%</td>
<td>.001</td>
</tr>
<tr>
<td>Pelvic rec</td>
<td>17%</td>
<td>6%</td>
<td></td>
</tr>
<tr>
<td>Dist mets</td>
<td>11%</td>
<td>3%</td>
<td></td>
</tr>
</tbody>
</table>

CHEMORADIATION SHOULD BE STANDARD OF CARE

“Grade A”
Stage IB2 : Approaches

- Surgery
- Radiation therapy
- Surgery + Radiation therapy
- Radiation therapy + Surgery
- Neoadjuvant chemo + Surgery
- Concurrent chemoradiation
### Stage Ib2: Role of Extrafascial Hysterectomy after RT

<table>
<thead>
<tr>
<th></th>
<th>RT(80Gy)</th>
<th>RT(75Gy+EFH)</th>
</tr>
</thead>
<tbody>
<tr>
<td>5y survival</td>
<td>61.4%</td>
<td>64.4%</td>
</tr>
<tr>
<td>Rec rate</td>
<td>43.3%</td>
<td>34.5%</td>
</tr>
<tr>
<td>Local rec</td>
<td>25.8%</td>
<td>14.4%</td>
</tr>
<tr>
<td>Distant rec</td>
<td>8.9%</td>
<td>15.9%</td>
</tr>
<tr>
<td>Adv events</td>
<td>54.8%</td>
<td>62.1%</td>
</tr>
</tbody>
</table>

No improvement in survival with addition of adjuvant hysterectomy

*(Keys 1997 GOG:RCT)*
Stage Ib2: Role of NACT

- **NACT + RT vs RT:**
  No difference in survival (13 RCTs)
- **NACT+ Surg vs Surgery + RT**
  Survival benefit at 3y in pts with tumour size >4 cm & >60 cc (Sardi et al 1997)
- **Concurrent chemoradiation better than RT in DFS & OAS in 5 RCTs**

**RCT comparing NACT+Surgery vs Concurrent chemoradiation recommended**
STAGE III & IV

Stage III  Carcinoma extends onto the pelvic wall, lower 1/3rd of vagina, hydronephrosis & malfunctioning kidney.
   III a  Extension to vagina.
   III b  Extension to parametria.

Stage IV  Carcinoma extends beyond the true pelvis, involves mucosa of bladder and rectum
   IV a  Spread of growth to adjacent organs
   IV b  Spread beyond pelvis, distant organs
Locally advanced disease

• Problems
  Increased local tumour bulk
  High incidence of pelvic & PA node mets
  Potential systemic spread

• Options
  Radiation therapy
  Concurrent chemo-radiation
  NACT + RT (7 RCTs : No benefit)
  NACT + Surgery
Stage IIb & III : Treatment

- Till recently, radical RT standard of care

- Current evidence: Radical RT (Ext + Brachy) with concurrent weekly cisplatin based chemo (40mg/sqm/week)

  **Rationale**
  - Cytotoxic to microscopic disease
  - Sensitization effect

  **Evidence**
  - GOG 85, GOG 120, GOG 123, RTOG 90-01, SWOG 8797
  - Meta analysis: Green et al. 2001, Lukka et al. 2002
## Locally Advanced Cancer Concurrent Chemoradiation: RCTs

<table>
<thead>
<tr>
<th>Author</th>
<th>CT</th>
<th>Surv %</th>
<th>%</th>
<th>p</th>
<th>RR death</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>CT+RT</td>
<td>RT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morris</td>
<td>PF</td>
<td>73</td>
<td>58</td>
<td>.004</td>
<td>0.52</td>
</tr>
<tr>
<td>Keys</td>
<td>P</td>
<td>84</td>
<td>68</td>
<td>.008</td>
<td>0.54</td>
</tr>
<tr>
<td>Peters</td>
<td>PF</td>
<td>81</td>
<td>63</td>
<td>.01</td>
<td>0.5</td>
</tr>
<tr>
<td>Whitney</td>
<td>PF</td>
<td>50.8</td>
<td>-</td>
<td>.018</td>
<td>0.72</td>
</tr>
<tr>
<td></td>
<td>H</td>
<td>39.8</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rose</td>
<td>P</td>
<td>64</td>
<td>-</td>
<td>.002</td>
<td>0.61</td>
</tr>
<tr>
<td></td>
<td>H</td>
<td>39</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PHF</td>
<td>66</td>
<td>-</td>
<td></td>
<td>0.58</td>
</tr>
</tbody>
</table>
Concurrent Chemoradiation
Result of RCTs

• 43 -46 % reduction in risk of death & recurrence
• The RR for death and recurrence remarkably similar in all studies
• Compelling evidence of survival benefit of 10-15% with concurrent cisplatin chemotherapy
Concurrent Chemoradiation

“These 5 major randomized phase III trials show that platinum based chemo when given concurrently with RT prolongs survival in women with locally advanced cervical cancer stages Ib2 - IVa as well as in women with stage I/IIa found to have metastatic pelvic lymph nodes, positive parametrial disease and positive surgical margins at the time of primary surgery”

Clinical announcement by NCI NEJM Feb1999
Concurrent Chemoradiation Results of Meta-analysis

- 19 RCTs between 1981 and 2000: 4580 randomised patients

- Increase in OAS by 12% & RFS by 16% (absolute benefit) ($p=0.0001$)

- Greater benefit in patients in stages IB2 and IIB

- Decrease in local and systemic recurrence ($p=0.0001$)

Stage IVa

Neoadjuvant chemotherapy in suitable cases followed by radiotherapy in responders

Rationale:

High response rates to CT in patients who have not received RT
Downstaging making it amenable to RT or Surgery

Evidence:
9 RCTs and one meta-analysis (Sheung 1998) have shown no benefit in PFS & OAS
Stage IVb

- Palliative chemotherapy: RCTs
  Cisplat+Ifosfamide better than cisplat alone
  Cisplat+Paclitaxel better than cisplat alone

- Palliative care
  - Pain relief
  - Psychological support
  - Role of radiation therapy and surgery needs to be defined
Pelvic Recurrence & Salvage

- **Post Surgery**
  - RT and/or Chemotherapy

- **Post Radiotherapy**
  - Central recurrence
    - Extrafascial / Rad hysterectomy
    - Ant/post/total pelvic exenteration

- **Lateral recurrence & distant mets**
  - Palliative chemotherapy
  - Re-radiation therapy
## Results Of Exenteration

<table>
<thead>
<tr>
<th>Author</th>
<th>Mortality</th>
<th>Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Douglas 1957</td>
<td>4.3%</td>
<td>22.0%</td>
</tr>
<tr>
<td>Parsons 1964</td>
<td>21.4%</td>
<td>21.4%</td>
</tr>
<tr>
<td>Brunschwig 1965</td>
<td>16.0%</td>
<td>20.1%</td>
</tr>
<tr>
<td>Brider 1967</td>
<td>10.0%</td>
<td>34.6%</td>
</tr>
<tr>
<td>Kreiger 1969</td>
<td>11.0%</td>
<td>37.0%</td>
</tr>
<tr>
<td>Ketcham 1970</td>
<td>7.4%</td>
<td>8.2%</td>
</tr>
<tr>
<td>Symmonds 1975</td>
<td>8.0%</td>
<td>32.3%</td>
</tr>
<tr>
<td>Morley 1976</td>
<td>2.9%</td>
<td>62.0%</td>
</tr>
<tr>
<td>Rutledge 1977</td>
<td>13.5%</td>
<td>33.4%</td>
</tr>
<tr>
<td>Averette 1984</td>
<td>10.4%</td>
<td>58.0%</td>
</tr>
</tbody>
</table>
EXTERNAL BEAM RADIATION THERAPY RECOMMENDATIONS

- WHOLE PELVIS WITH AP/PA OR FOUR FIELD BOX TECHNIQUE
- DOSE DEPENDING ON THE STAGE
- BORDERS
MIDLINE BLOCK/CORNER SHIELDS

• MIDLINE BLOCK
• FOR DOSE ESCALATION

• CORNER SHIELDS
• TO REDUCE G.I TOXICITIES

(Level 2 Evidence)
BRACHYTHERAPY

• BRACHYTHERAPY: INTEGRAL PART OF RADIATION THERAPY

• PATTERNS OF CARE STUDIES CONFIRM SIGNIFICANT REDUCTION IN RECURRENCES AS WELL AS COMPLICATIONS

• PRECISE APPLICATION OF THE CATHETERS ESSENTIAL TO OBTAIN ABOVE RESULTS - EXPERTISE AND SKILLS

INTRACAVITARY- TIME TESTED (> 70 YRS)

INT. COMMISSION ON RAD. UNITS- (ICRU-38) RECOMMENDATIONS
## RECOMMENDED TOTAL RADIOTHERAPY DOSES

<table>
<thead>
<tr>
<th>Stage</th>
<th>Ext. RT Pelvis</th>
<th>ICRT Point ‘A’</th>
<th>Total Dose ‘A’</th>
</tr>
</thead>
<tbody>
<tr>
<td>IA</td>
<td>0</td>
<td>50-60</td>
<td>50-60</td>
</tr>
<tr>
<td>IB/IIA</td>
<td>45</td>
<td>30-35</td>
<td>75-80</td>
</tr>
<tr>
<td>IIB</td>
<td>45-50</td>
<td>35-40</td>
<td>85</td>
</tr>
<tr>
<td>IIIB</td>
<td>50</td>
<td>35-40</td>
<td>85-90</td>
</tr>
</tbody>
</table>

- Radiotherapy treatment to be completed within 8 weeks

*IJROBP 1993,1995*
Thank You